Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8810159 | 0.92 | MEN1 (0.44) | MEN1ALDH1A1GAAKMT2ACD274 | |
| SCHEMBL8808400 | 0.85 | FFAR1 (0.44) | MRGPRX4 | |
| SCHEMBL8810000 | 0.78 | S1PR1 (0.37) | MEN1ALDH1A1GAAKMT2AMRGPRX4 | |
| SCHEMBL8810005 | 0.76 | — | — | |
| SCHEMBL8808914 | 0.76 | MRGPRX4 (0.45) | MRGPRX4 | |
| SCHEMBL8810263 | 0.75 | MRGPRX4 (0.43) | MRGPRX4 | |
| SCHEMBL8807145 | 0.74 | NPC1 (0.44) | CD274PDCD1MRGPRX4 | |
| SCHEMBL8807660 | 0.73 | — | — | |
| SCHEMBL8808916 | 0.72 | FFAR1 (0.46) | MEN1ALDH1A1GAAKMT2ACD274 | |
| SCHEMBL8810163 | 0.69 | MRGPRX4 (0.41) | MEN1ALDH1A1GAAKMT2AMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0805802-A1 | SUBSTITUTED PHENYL COMPOUNDS AS ENDOTHELIN ANTAGONISTS | RHONE-POULENC RORER LIMITED (GB) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022978-A1 | SUBSTITUTED PHENYL COMPOUNDS AS ENDOTHELIN ANTAGONISTS | RHONE POULENC RORER LIMITED (GB) | 1996-08-01 | — | — | WO | disclosed |